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Abstract 
Chronic intranasal administration of fibrillar structures of proinflammatory S100A9 
protein impaired passive avoidance learning in old C57Bl/6 mice. Combined treatment 
with S100A9 fibrils and antibodies to glutamate was followed by an increase in 
horizontal locomotor activity of animals in the open-field test and did not disturb spatial 
memory. 
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The increase in the incidence of cognitive disorders in elderly and old people is an urgent 
problem of modern society. Alzheimer’s disease (AD) is the most common type of 
dementia. The major symptoms of this chronic neurodegenerative disease include 
memory, thinking, and behavioral disturbances [1]. Little is known about the mechanisms 
of cognitive deficit in AD [3]. Disturbed conformation of some proteins and peptides is a 
molecular mechanism leading to apoptotic death of neurons and subsequent development 
of dementia. Some misfolded proteins can form pathological aggregates that are 
deposited in brain parenchyma (e.g., senile plaques of β-amyloid protein [2,5]) and 
induce degeneration of neurofilaments with the formation of neurofibrillary tangles. 
These changes contribute to activation of microglia, induction of the endosomal-
lysosomal signaling system in cells [2], inhibition of tissue oxidative systems [7], 
neuroinflammation [12], development of glutamate excitotoxicity [10], and apoptosis [1]. 
Along with Aβ1-42 and tau protein playing a key role in the mechanisms of AD, much 
attention is paid to proinflammatory S100A9 protein whose expression increases in the 
microglia (e.g., in the temporal cortex of the brain) during inherited and sporadic AD 
[14]. S100A9 folding is sometimes impaired with the formation of toxic oligomeric and 
fibrillar structures of S100A9 (S100A9-FS) and their accumulation (aggregation) in the 
brain [13,14]. These changes can serve as a differential marker of early cognitive deficit 
during AD [6]. Previous studies showed that intranasal administration of monospecific 
antibodies to glutamate (AB-GL) produces an antiamnesic effect in the model of AD 
induced by injection of a neurotoxic fragment Aβ25-35 into the Meynert nucleus of adult 
rats [4]. This work was designed to study the effect of in vitro synthesized amyloidogenic 
S100A9-FS on spatial memory formation during passive avoidance conditioning and 
locomotor activity of animals. We also evaluated the influence of combined treatment 
with AB-GL and S100A9-FS (intranasally) on old C57Bl/6 mice.  
MATERIALS AND METHODS  
Experiments were performed on 12-month-old male C57Bl/6 mice (n=60) weighing 
31.0±1.0 g. The animals were maintained under standard conditions (12:12-h light/dark 
regimen) and had free access to water and food. To obtain S100A9-FS, native protein 
was dissolved in 10 mM sodium-phosphate buffer (pH 7.4), sonicated for 15 min, and 
centrifuged on an Eppendorf Centrifuge 5417R at 14,000 rpm. The supernatant was 
filtered through 0.22-µ filters (Millex) and incubated (concentration 2 mg/ml) in 10 mM 
sodium-phosphate buffer (pH 7.4) at 37 
o
C and constant agitation (Eppendorf 
Thermomixer Compact) for 24 h. The formation of amyloid S100A9-FS was estimated 
from variations in fluorescence of a staining agent (thioflavin T). Morphological 
characteristics of S100A9-FS were evaluated by atomic-force microscopy [11]. 
Polyclonal monospecific AB-GL were obtained by immunization of Chinchilla rabbits 
with a conjugate of glutamate and BSA. This conjugate was obtained with a bifunctional 
reagent glutaraldehyde [13]. The γ-globulin fraction of antibodies was precipitated from 
serum samples of immunized rabbits with ammonium sulfate (40% saturation) and 
dialyzed. The γ-globulin fraction was purified from anti-BSA antibodies by means of 
affinity chromatography (CNBr-Sepharose 4B [Sigma] as a sorbent with immobilized 
BSA), lyophilized, and stored at 4 
o
C. The content of AB-GL in serum samples from 
immunized rabbits was estimated by solid-phase ELISA. The conjugate of glutamate and 
horse γ-globulin (heterologous protein carrier) was used as a test antigen. The titer of 
AB-GL was 1:1024±1:16. C57Bl/6 mice were divided into 5 equal groups. Control 
animals received physiological saline (4 µl) intranasally for 14 days. Mice of two 
treatment groups intranasally received S100A9-FS (in vitro individual preparation, 0.48 
mg/kg in 4 µl). Animals of the two other groups were treated with S100A9-FS and 
ABGL (250 µg/kg in 4 µl). In series I, the behavior of mice was studied in the open-field 
test. We recorded the distance of running, time of locomotion and rest, and number of 
vertical rearing postures. Locomotor activity was evaluated in an automated test with 
AutoTrack software (OptoVarimex system, Columbus Instruments) for 0-6 min. In series 
II, passive avoidance reflex was conditioned in mice. The experimental chamber 
consisted of light (15.5×15.5×19 cm) and dark (9×9×17 cm) compartments and metal 
grid floor consisting of rods 0.3 cm in diameter and spaced 0.9 cm apart. Both chambers 
were connected through a gate with a guillotine door. On day 1, the mice were 
individually placed into a light compartment illuminated with a 100-W lamp and allowed 
to familiarize with the chamber for 60 sec. By the end of this session, the door between 
two compartments was opened. Due to innate hole exploratory behavior typical of 
rodents, the animal moved to a dark compartment. The latency of transition (LT1) was 
recorded. When the animal appeared in a dark compartment (with all four limbs and 2 / 3 
of the tail), the door was closed and electrocutaneous stimulation (0.3 mA, 1.0 s) was 
applied, after which each animal was immediately removed and placed in the home cage. 
The acquired skill was tested after 24 h. The animal was placed in an illuminated 
compartment for 30 sec to familiarize with the conditions. The door was opened, and the 
latency of transition into a dark compartment was recorded (LT2). The behavior of 
animals was studied for 300 sec (beginning from the door opening on days of training 
and testing). The difference between LT of animal transition into the dark compartment 
during learning and 24 h after training (ΔLT) reflected the memory retention. The results 
were analyzed by Statistica 6.0 software. Several independent samples were compared by 
one-way nonparametric analysis of variance (Kruskal-Wallis H test) followed by post-
hoc analysis (Mann-Whitney U test). The data are presented as M±m. The critical level of 
statistical significance in null hypothesis testing was taken as 0.05.  
 RESULTS AND DISCUSSION 
The size of S100A9-FS was ~3 nm. The intensity of ThT fluorescence during their 
formation was elevated by 5.6 times. The time of locomotion in the open-field test for 
S100A9-FS-receiving mice was 20.4% greater than in controls. However, the mean free 
path length (locomotor distance) did not differ from the controls. Intranasal co-
administration of S100A9 fibrils with AB-GL led to a 32.0% increase in open field free 
path length, an elevation of ambulation time by 35.7% but a 57.0% reduction in the 
immobility time compared with controls. There was also a 11.3% increase in ambulation 
time (time of locomotion) and decreased immobility time by 26.0% in these animals 
compared with the group treated with S100A9 fibrillar structures alone (Table 1). 
 
 
 
In experiments on passive avoidance behavior 15 days after initiation of daily S100A9 
fibril administration, the aged mice developed a spatial memory deficit which was 
manifested by a  reduction of ΔLT to 28.9 ± 21.6 (P<0.01), compared with a control 
group (ΔLT = 144, 24.6 + 0. In the animal group intranasally treated for 14 days with 
S100A9 fibrillar structures combined with AB-GL, the degree of reminding (ΔLT= 117.9 
± 34.2 s) did not differ from that displayed by the controls (Fig 1.) 
These findings have disclosed an amnestic effect expressed on passive avoidance 
behavior incited by S100A9 fibrillar structures in aged mice. This action potentially 
stems from the development of glutamate excitotoxicity and subsequent apoptotic 
neuronal death in relevant brain structures. Hence, intranasal co-administration of AB-GL 
with S100A9 fibrils reversed the passive avoidance behavioral disruption through a 
protective antiamnestic action probably originating from AB-GL binding any glutamate 
excess thereby reducing the prospect of neuronal apoptosis [8, 9]. The marked increase in 
horizontal locomotor activity in the open field following co-administration of AB-GL 
with S100A9 fibrils reflected unhindered orienting-exploratory activity. This would 
therefore serve as additional support for reduced toxic effects of both glutamate and 
S100A9 fibrillar structures themselves. 
In conclusion, the results of the current study demonstrated on one hand, that 
amyloidogenic fibrillar species of the pro-inflammatory protein S100A9 are capable of 
instigating spatial memory impairment. This may be a component mechanism in the 
molecular sequence leading to cognitive deficits implicated in neurodegenerative 
diseases. On the other hand, intranasally administered monospecific antibodies to 
glutamate displayed protective effects and reversed spatial amnestic activity in aged 
mice. 
 
 
Figure 1. Effects of intranasal administration of the pro-inflammatory protein S100A9 
amyloidgenic fibrillar structures individually or in co-administration with nonspecific antibodies 
to glutamate on passive avoidance behavior in comparison with control aged C57BL/6 mice.  
                   The ordinate shows ΔLT (s); * - P < 0.05 compared to control. 
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